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SUMMARY 
Seizures, including electrically induced seizures (ECS), activate the hypothalamo-pituitary-ad~nal 
(I-IPA) axis in rats. The present studies were undertaken to characterize the effects of ~eated  ECS on 
hormone release and brain adrenal steroid receptors. Repeated ECS led to an increase in adrenal 
weight, an increase in the corticosterone response to the eighth seizure compared to the first seizure, and 
an increase in basal plasma corticosterone levels at the trough of the circadian rhythm. Despite 
increased plasma corticosterone levels at the time of sacrifice, there were no decreases in adrenal steroid 
receptor numbers in hypothalarnus, cortex or hippocampus. In chronic ECS-treated rats which were 
adrenalectomized overnight to remove glucocorticoids, an increase in Type I (mineralocorticoid) steroid 
receptors occurred in both hippocampus and cortex. These data suggest that chronic ECS has atrophic 
effect on Type I receptors and that the higher levels of corticosterone resulting from chronic ECS do not 
induce adrenal steroid receptor down-regulation. 
INTRODUCTION 
ONE of the most replicated biological findings in psychiatry is the demonstration of abnormal HPA 
axis regulation in depression (Sachar et  al., 1973; Carroll et  al., 1976a; 1976b; 1981; Halbreich et 
al., 1985; Pfohl et  al., 1985; Linkowski et  al., 1987; Poland et  al. ,  1987; Rubin et  al., 1987). 
Although hypercortisolemia has not always been demonstrated, the failure to shut off cortisol 
secretion in response to dexamethasone has been demonstrated in a number of  studies examining 
depressed subjects (Carroll et  al., 1976a; 1976b; 1981; Pfohl et  al., 1985; Poland et  al., 1987). 
Most studies agree that the HPA axis normalizes following effective anti-depressant treatment 
(Holsboer et  al., 1982; Greden et  al., 1983). However, one of the most effective antidepressant 
treatments, electroconvulsive treatment (ECT), is itself a powerful stimulus to the HPA axis. 
Several studies have shown that ECT stimulates the release of ACTH from corticotrophs and that 
repeated ECT may affect the HPA axis (Allen et  al., 1974; Alexopoulos et  al., 1983; Aperia et al., 
1984; Misiaszek et  al., 1984; Weizman et  al., 1987; Ghadirian et  al., 1988). 
Glucocorticoids such as corticosterone bind to two different receptors in brain, i.e. the gluco- 
corticoid or Type lI receptor and the mineralocorticoid or Type I receptor;, these receptors may reg- 
ulate different physiological functions (Reul & de Kloet, 1985). They are collectively referred to 
as "adrenal steroid" receptors. The current study was undertaken in rats to characterize the effects 
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of  repeated e lec t r ica l ly  induced  seizures  (ECS)  on cor t icot roph and adrenal  responses ,  and whether 
ECS affects  bra in  adrenal  s teroid receptors .  
METHODS 
Male Sprague Dawley rats were obtained from Charles River (Portage, MI) and housed in groups (five to six per 
cage) in a controlled environment on a 12-hr light-dark schedule (lights on at 0700h). ECS was administered in the 
morning between 0830h and 1030h by delivery of a brief electrical pulse (70 mAmp, 0.15 sec, 60 Hz) via ear clip 
electrodes. Rats were held in the investigator's hand for the duration of the seizure, approximately 30 sec. For 
chronic studies, the rats were returned to their home cage following the termination of the seizure. Unless other- 
wise indicated, for acute studies, animals were decapitated 3-5 min after the convulsive stimulus. For chronic 
studies, rats received daily ECS for eight days and were decapitated 24 hr following their last treatment, except 
where further indicated. Animals were decapitated in the immediately adjacent room within 30 see of removal 
from their home cage. Trunk blood for hormonal assays was obtained at the time of decapitation. 
To assess corticotroph release into plasma following seizure, a radioimmunoassay (RIA) for 13-endorphin was 
used. I]-endorphin and ACTH are synthesized as part of the same precursor, proopiomelanocortin, which is pro- 
cessed within secretory granules to yield equimolar amounts of ACTH and [~-endorphin/~-lipotropin. Prior to RIA, 
plasma samples were extracted with a Sep-Pak (Waters, Milford, MA) extraction procedure (Cahill et  al., 1983). 
The 13-endorphin antibody was a gift of Huda Akil. It was used at a final dilution of 1:40,000 as described pre- 
viously (CahiU et  al. ,  1983). The assay buffer was 150 mM phosphate, pH 8.2, with 0.1% bovine serum albumin 
(Fraction V, RIA grade, Sigma, St. Louis, MO). [l~I] ~-endorphinl_31 was used as the radiolabelled tracer, and ~- 
endorphinl_31 for the unlabelled standard. The samples and standards were dissolved in 0.1% human serum 
albumin (lISA, Fraction V, Sigma, St. Louis, MO), pH 3.0 with 1N HC1. The equivalent of 0.25 ml plasma was 
added per assay tube. 
The ACTH antibody also was a gift of Huda Akil. The antibody was used at a final titer of 1:80,000. The assay 
buffer was 150 mM phosphate, pH 7.4, with 50 mM NaCI, and 0.1% polylysine. The samples and standards were 
dissolved in 0.1% human serum albumin, pH 3.0 with 1N HC1. [t2-SI]ACTHl_39 was used as the radiolabelled 
tracer, and ACTH1_39 was used for the unlabelled standard: The equivalent of 0.5 ml rat plasma was added per 
assay tube. 
Corticosterone was assayed with a competitive protein binding (CBG) assay. [3H]corticosterone was used as 
the radiolabeUed ligand, and corticosterone as the unlabelled standard. Samples were extracted with Sep-Pak, fol- 
lowed by an ethanol-saline extraction prior to assay. Fuller's earth was used as the absorbant to separate bound 
from free ligand. 
For adrenal steroid receptor assays, animals were adrenalectomized 16 hr before morning sacrifice. The 
adrenalectomies were done under Metofane anesthesia with a dorsal surgical approach. Animals were observed 
until they were fully awake and then were returned to their home cages. They were given 0.9% saline overnight in 
place of water. Following sacrifice by decapitation, the brains were rapidly removed and dissected into the follow- 
ing brain regions: hypotlmlamus, liippocampus and parietal cortex adjacent to the hippocampus. These regions 
were frozen on dry ice and stored at -80" C. 
On the day of the glucocorticoid binding assay, the frozen brain regions were homogenized with 15 strokes of a 
hand held homogenizer in 10 mM ice cold "lYis buffer, pH 7.4, with 1 mM EDTA, 10% glycerol, 20 mM molybdate 
and 1 mM dithiothreitol. The homogenates were centrifuged at 40,000 RPM in a Ti-50 rotor (145,000g) in a 
Beckman ultracentrifuge for 30 rain. The supernatant (cytosol) was transferred to another tube and kept on ice 
until use. For estimates of within-group variability and treatment effects, a single-point assay was conducted for 
the three brain regions in individual animals. This assay used a saturating concentration (10 riM) of [3H]dexa- 
methasone (Amersham, Arlington Heights, IL, specific activity=70-97 Ci/mmol). Type II (glucocordcoid, (JR) 
binding is defined as the portion of binding displaced by 500rim RU 26988, a selective Type II llgand (Moguilew- 
sky & Raynand, 1980). Type I (minezalooorticoid, MR) binding is defined as the portion of binding not displaced 
by RU 26988 but displaced by 2.5 gM corticosterone. The samples were incubated overnight at 4" C, and bound 
ligand was separated from free with 1 ml Sephadex LH-20 minicolumns. The eiuate from the column was col- 
lected directly into scintillation vials, scintillation cocktail was added, and the samples were counted in a Packard 
scintillation counter. All samples were run in triplicate, and the triplicates averaged to calculate fmol bound. A 
portion of the original cytosol was saved and assayed for protein content by the Bio Rad protein assay. The values 
are expressed as fmol bound/rag protein. In addition to single point estimates of Braax, hippocampal and cortical 
tissue from each rat per treatment group was pooled for Scatchard plot estimates of K o between groups. The 
pooled homogenates were processed identically to the single point samples. Aliquots were incubated with five 
concentrations of [3H]dexamethasone between 0.3nM and 10 riM. Type I and Type 1I binding were definedand 
quantitated for each concentration of [3H]dexamethasone, as described above. 
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RESULTS 
ECS resulted in a prompt rise in plasma ACTH and I~-endorphin in rats at 3 - 5  min, supporting 
parallel release of these two hormones with ECS. The mean data for three experiments are shown 
in Fig. 1 (Student's t test, p = 0.001, p = 0.0027 and p = 0.001 for each experiment). 
z 6 0 0 -  
O_ 














[ ]  13-ENDORPHIN 




ACTH and 13-Endorphin Response to Acute ECS 
I~G. 1: Plasma ACTH and ~-endorphin response to acute  ECS 5 mln follow- 
Ing the onset  of seizure. The data are the mean  of three experiments. For 
each experiment there were six to 10 ra ts  per group (total 22 ra t s  per  groupl. 
A time course of the release of 13-endorphin and corticosterone into plasma was compared 
between the first and eighth ECS sessions and is shown in Figs. 2 and 3. Although the initial 
endorphin response appears to be greater on the eighth session than the first session, there was no 
difference in the ~-endorphin response to the first or eighth ECS session (F=2.37, p =N S ,  two-way 
ANOVA for 0 - 6 0  min; F=2.8, p=NS,  two-way ANOVA for 0 - 5  min). In contrast, there was a 
significant difference in the glucocorticoid response to the first and eighth ECS (two-way ANOVA: 
F=21.8, p=0.0001 for acute response to ECS; F=12.2, p=0.0008 for repeated treatment; no 
significant interactions). As evident in Fig. 3, chronic ECS led to an increase in basal steroid 
levels. This was replicated in two additional experiments (Student's t test p = 0.001 and p = 0.03). 
The discrepancy between corticotroph secretion as reflected in l~-endorphin response and adrenal 
response as reflected in corticosterone levels may be explained by adrenal hypertrophy: There was 
a significant increase in adrenal weight in the chronic ECS rats (control= II.4_+0.57 mg/100 g 
BW; chronic ECS= 14.7_+ 1.1 rag/100 g BW, p =0.02, Student's t test; uncorrected for BW, control 
adrenals = 39.6_+ 2.6 mg, chronic ECS adrenal = 40.3_+ 2.8 rag). 
To measure Type I and Type II adrenal steroid binding, groups of control and ECS rats were 
adrenalectomized 16 hr before decapitation (seven rats per group). Glucocorticoid binding was 
measured in the hypothalamus, hippocampus and cortex. There was no difference observed 
between control and ECS rats in Type II binding in any brain region (F= 1.4, p = NS). There was a 
small number of Type I receptors in the cortex and a larger number of receptors in the hippocam- 
pus; these were increased in the chronic ECS rats (F= 6, p = 0.02, two-way ANOVA). There was a 
very small but detectable number of Type I receptors in the hypothalamus; the number was so 
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FIG. 2 (above. left}: Comparison ~ p1e~m~_ ~-endorph~ response to the first and eighth ECS. The graphs show 
the mean and SEM data for seven ~ / ~  at each tlme point. 
l~a. 3 (above. right}: C o m p ~  ~ [ ~ e r o n e  response to the first and eighth ECS from 0-120 rnLn. The 
graphs present the mean and SEM data for seven rats/group at each time point. 
small (less than 20% of cortex) that quantitative estimates were unreliable. A repeat experiment m 
which rats were adrenalectomized 20 hr before sacrifice demonstrated a similar increase in Type I 
receptors in the hippocampus (F=4.8, p < 0 . 0 5 ,  two-way ANOVA), with no change in Type II 
receptors in hypothalamus, hippocampus or cortex (F=.35, p f N S ,  two-way ANOVA, seven rats 
per group). Consequently, these dam demonstrate an increase in the number of Type I adrenal 
steroid receptors, with no change in Type II receptors, following chronic ECS. The mean data for 
the two experiments are shown in the Table. Scatchard plots of pooled control and ECS rats 
demonstrated similar KDS for the Type I receptor in hippocampus between groups (mean of two 
experiments: Kv=2.4 nM for control and 1.2 nM for ECS; B ~ = 2 7  fmol/mg protein for control 
and 33 fmol/mg protein for ECS), confirming that the increase in binding was due to an increase in 
receptor number in the chronic ECS rats. 
E ~ I  " OF CHRONIC ~ ON TY~ I ~ TYPE II GMJCOCO~rIcoID I ~ : P ' r O R S  
: i i i i i . i  i 
Sinsle-poLqt estimates 
HypothaIamus II 74.3 + 9.9 74.8 + 8.5 
Hiplx}campus I 26.8 + 5.3 41.8 + 5.6 
II 124 + 11.5 114 + 11.5 
Cortex I 7.4 + 1.5 10 + 1 
II 125 + 5 110 + 5 
Scatchard Data 
Hippocampus 
Kt} I 2.4 1.2 
II 0.6 0.55 
Bma x I 27 33 
II 125 129 
Mean (± SEMs} of two expe~ments (13 rats per group}. 
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To confirm the lack of effect of elevated plasma 
corticosterone on Type II receptors, adrenal steroid 
receptor binding in brain was also evaluated in 
intact (non-adrenalectomized) rats. Since the Type I 
receptor is bound extensively by endogenous hor- 
mone even under non-stress conditions, in intact 
rats the majority of the adrenal steroid binding rep- 
resents Type II (glucocorticoid) receptor binding, 
(Reul & de Kloet, 1985; Spencer et aL, 1990). In 
these intact rats, only total binding (10 nM [3H]- 
dexamethasone minus excess corticosterone) was 
measured. Animals were sacrificed 24 hr following 
the seventh ECS session (seven rats per group). As 
expected, basal corticosterone levels in the chronic 
ECS rats were significantly increased at the time of 
decapitation (control vs. ECS, p = 0.029, unpaired 
two-tailed t-test) (Fig. 4). There was no significant 
effect of treatment on receptor number for the ECS 
rats in hypothalamus, cortex or hippocampus. This 
confirms the adrenalectomy data demonstrating no 
decrease in Type II receptor binding despite ele- 
vated plasma glucocorticoid levels. 
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Basal Steroid Levels Following Chronic ECS 
F[G. 4: Comparison of basel~.e corticosterone 
levels in naive, unhandled  ra t s  (control) or rats 
which  received daffy ECS for seven days. The 
m e a n  da ta  f rom two e x p e r i m e n t s  are shown.  
Cor t i cos te rone  s a m p l e s  were  ob ta ined  in the  
morning at the nadir  o~ the rat circadian rhythm 
(control], and 24 h r  following the seventh ECS. 
DISCUSSION 
Electrically induced seizures can act as a stimulus tO the HPA axis. Several studies have indi- 
cated that ECT releases ACTH; the effect of repeated ECT on the corticotroph response is more 
controversial (Allen et al., 1974; Alexopoulos et al., 1983; Weizman et al., 1987; Herman et al., 
1989a). Herman et al. (1989a) demonstrated in rats an increase in corticotropin releasing hormone 
messenger RNA (CRH mRNA) in the paraventricular nucleus (PVN) of hypothalamus following 
seven daily ECS sessions. This increase in CRH mRNA was accompanied by a decrease in CRH 
content, suggesting an increased release of CRH into hypophyseal portal blood with repeated ECS. 
This increased CRH drive resulted in an increase in ACTH and ~-endorphin content of anterior 
lobe corticotrophs, presumably because of the increase in CRH-driven POMC biosynthesis and 
processing. An increase in the ACTH and ~-endorphin content in anterior lobe corticotrophs was 
also observed in the current experiments (data not shown). This increased content was not accom- 
partied by increased ~-endorphin release with repeated seizures. These data are in agreement with 
previously published data on repeated footshock stress, which demonstrated a two-fold increase in 
anterior lobe ACTH and 13-endorphin peptide content, but a similar release of ACTH and ~-endor- 
phin with the first and 15th footshock stress (Young & Akil, 1985). However, repeated ECS did 
result in increased corticosterone levels, both at rest and following the eighth seizure. This failure 
to detect increased corticotroph secretion, as reflected by ~-endorphin measures, despite evidence 
of increased adrenal corticosterone secretion, may be explained by adrenal hypertrophy, with 
resulting increased sensitivity to ACTH. In addition, the elevated resting corticosterone levels 
may act through intermediate feedback to inhibit corticotroph secretion in response to seizures. 
Thus, the elevated glucocorticoid plasma levels may result in changes in feedback signals to the 
HPA axis, as communicated through adrenal steroid receptors. 
The demonstration of normal numbers of adrenal steroid receptors in the .face of elevated 
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steroid levels is unexpected. The measurements of Type I and Type II receptors in overnight 
adrenalectomized rats demonstrated an increase in Type I adrenal steroid receptors following 
chronic ECS. The data from intact rats confirm the lack of down-regulation of Type II receptors in 
chronic ECS rats. These results indicate that the hypersecretion of glucocorticoids resulting from 
ECS treatment is not sufficient to produce a down-regulation of hippocampal adrenal steroid 
receptors. These data are in apparent disagreement with the data of Sapolsky et al. (1984), who 
demonstrated that chronic stress and glucocorticoid administration down-regulate adrenal steroid 
receptors in the hippocampus. This difference may be secondary to differences in the stressors and 
the length of time that glucocorticoids are elevated, or to the absolute levels of corticosterone 
achieved. It suggests that seizures have widespread effects on neuronal functioning apart from 
their activation of the HPA axis, and they may stimulate a factor that has a trophic effect on 
adrenal steroid receptors. Data from chronic ethanol-treated rats also demonstrated that the ele- 
vated glucocorticoid secretion following daily ethanol administration did not lead to down-regula- 
tion of adrenal steroid receptors (Spencer & McEwen, 1990). In one of two experiments an 
increase in Type I receptors also was observed. Again, ethanol may have other generalized neu- 
ronal effects that counteract the elevated glucocorticoid levels. 
An alternate explanation may involve regulation of Type I receptors by Type II receptor occu- 
pancy. Reul et  al. (1989) demonstrated an increase in Type I binding in adrenalectomized rats 
given dexamethasone chronically in their drinking water and hypothesized that either the 
efficiency of translation of Type I mRNA or the stability of the Type I protein was affected by 
Type I1 receptor occupancy. However, dexamethasone is a synthetic steroid that occupies Type II 
receptors, with little occupation of Type I receptors in vivo.  In contrast, corticosterone, the natural 
steroid, should occupy both Type I and Type II receptors in vivo.  Consequently, it is unclear 
whether this possible modulation by Type II receptors is sufficient to overcome the expected 
effects of occupancy of Type I receptors by corticosterone. 
The physiological significance of this observed increase in Type I receptors in the hippocampus 
is unclear. The hippocampus has long been regarded as an inhibitory input to the HPA axis (cf. 
Sapolsky, 1986 for review). Herman et  al. (1989b) demonstrated that removal of the hippocampus 
leads to increased CRH mRNA in the PVN as well as an induction of arginine vasopressin mRNA 
(AVP, another ACTH secretagogue) in the CRH neurons. This increase in CRH and AVP mRNA 
occurs despite the significantly elevated plasma ACTH and corticosterone levels in these hip- 
pocampectomized rats. Although different regions of the hippocampus may have different effects 
on the HPA axis, these experiments point out the importance of the trans-synaptic inhibitory input 
from the hippocampus to the PVN to inhibit CRH and subsequent ACTH secretion. However, 
whether this inhibitory input acts through occupation of Type I or Type II adrenal steroid receptors 
in the hippocampus has not yet been determined. In a study utilizing the administration of specific 
Type I and Type II receptor antagonists in vivo,  blockade of both receptor types extended the dura- 
tion of the corticosterone response to acute stress (Ratka et  al. ,  1989). de Kloet et  al. (1988) 
demonstrated that local injection of RU 38486 (a Type II antagonist) into the dentate gyrus of the 
hippocampus did not initiate an HPA axis response, although it was able to affect behavioral 
responses, whereas Injection of RU 38486 into the PVN did result in HPA axis disinhibition. 
These data suggest that Type II receptors in the dentate gyrus are not involved in the inhibitory 
influence of the hippocampus on HPA axis function. Although it is not yet possible to delineate 
the roles of both the Type I and Type II receptors in feedback regulation in vivo,  there also are 
studies that suggest both positive and negative feedback effects of glucocorticoids can occur in 
vivo (James et  al., 1965; Jones et al., 1972; 1974; Krieger et al.,  1975; Fehm et al., 1977; 1979; 
Mahmoud et  al . ,  1984; Young & Akil, 1988). A possible positive feedback effect of gluco- 
corticoids on their own release would be consistent with the effects we have observed in the rats 
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receiving chronic ECS, i.e. both increased Type I receptors and increased basal plasma corticos- 
terone levels. 
In conclusion, repeated ECS led to an up-regulation of  some elements of  the HPA axis, particu- 
larly CRH secretion, A C T H  cort icotroph content and adrenal steroid levels. The increase in 
adrenal steroid levels did not lead to the expected decrease in adrenal steroid receptors in brain; in 
fact, Type I adrenal steroid receptors were significantly elevated. The relationship between 
increased plasma glucocorticoid levels and increased adrenal steroid receptors in brain remains to 
be elucidated. It is possible that the increased adrenal steroid receptor numbers are secondary to a 
more general ized effect of  seizures than stimulation of  the HPA axis. Whether  the observed 
changes in adrenal steroid receptors following repeated seizures play any role in the normalization 
of  the DST in man following successful treatment with ECT is unknown. 
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